A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Desmethyl Imatinib D4 - Request Quote

Picture of Desmethyl Imatinib D4

Desmethyl Imatinib D4

SZ CAT No:SZ-I004D04
CAS No
NA
Mol.F.
C28H25D4N7O
Mol.Wt.
483.6
Inv. Status
Synthesis on demand
Rel. CAS No404844-02-6 (Unlabeled)

Chemical Name :

Shipping Temperature :

HSN Code :

Country of Origin :

Smiles :

Usage Note:

Desmethyl Imatinib D4 is chemically N-(4-Methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)-4-(piperazin-1-ylmethyl)benzamide-2,3,5,6-d4. Desmethyl Imatinib D4 is supplied with detailed characterization data compliant with regulatory guideline. Desmethyl Imatinib D4 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Imatinib.

The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.

Applications & Regulatory Use Cases

buy high quality Desmethyl Imatinib D4

Purchase Desmethyl Imatinib D4

Desmethyl Imatinib D4 suppliers

Desmethyl Imatinib D4 manufacturers

Desmethyl Imatinib D4 price

Order Desmethyl Imatinib D4

Enquire Desmethyl Imatinib D4

Desmethyl Imatinib D4 cost

Desmethyl Imatinib D4 Supplier

Desmethyl Imatinib D4 Distributor

Desmethyl Imatinib D4 for Method Validation

Imatinib Reference Standard

Desmethyl Imatinib D4 for ANDA Filing

Desmethyl Imatinib D4 for Forced Degradation Studies

Desmethyl Imatinib D4 Identification Standards

Desmethyl Imatinib D4 for DMF Filing

ℹ️

Disclaimer

SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.

SynZeal will update these details as per new developments or findings in product specifications without further notice.

,